Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9318622 | 0.87 | KDM4E (0.47) | SLC6A3SLC6A4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9320103 | 0.83 | SLC6A3 (0.43) | SLC6A3SLC6A4ATMKDM4EALDH1A1 | |
| SCHEMBL2206554 | 0.82 | ADORA3 (0.50) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL19195619 | 0.77 | KDM4E (0.49) | SLC6A3SLC6A4ATMKDM4EALDH1A1 | |
| SCHEMBL4554338 | 0.76 | ALOX5 (0.50) | SLC6A3SLC6A4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5032882 | 0.74 | KDM4E (0.52) | SLC6A3SLC6A4ATMKDM4EALDH1A1 | |
| SCHEMBL2205703 | 0.74 | KDM4E (0.43) | ATML3MBTL1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9318354 | 0.74 | KDM4E (0.45) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5072166 | 0.73 | SLC6A3 (0.59) | SLC6A3SLC6A4ATMKDM4EALDH1A1 | |
| SCHEMBL18539206 | 0.73 | SLC6A3 (0.59) | SLC6A3SLC6A4ATMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737815-B1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-7981907-B2 | Thio-substituted biarylmethanesulfinyl derivatives | CEPHALON, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981907-B2 | Thio-substituted biarylmethanesulfinyl derivatives | CEPHALON, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090062284-A1 | Thio-Substituted Biarylmethanesulfinyl Derivatives | CEPHALON, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062284-A1 | Thio-Substituted Biarylmethanesulfinyl Derivatives | CEPHALON, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-7449481-B2 | e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue | CEPHALON, INC. (US) | 2008-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062284-A1 | Thio-Substituted Biarylmethanesulfinyl Derivatives | AANAT, SNCA, NAT1 | SLC6A3 177/4885SLC6A4 218/4885ATM 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.